Buformin

Buformin

SCHEMBL104609

CCCCNC(=N)NC(=N)N.Cl.c1ccsc1

nearest known ligand 0.34

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO

The experimentally established mechanism targets of Buformin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
GRIN2D known ✓ O15399 2/20 0.34
GRIN3B known ✓ O60391 2/20 0.34
GRIN1 known ✓ Q05586 2/20 0.34
GRIN2A known ✓ Q12879 2/20 0.34
GRIN2B known ✓ Q13224 2/20 0.34
GRIN2C known ✓ Q14957 2/20 0.34
GRIN3A known ✓ Q8TCU5 2/20 0.34
SIGMAR1 known ✓ Q99720 1/20 0.34
ACHE known ✓ P22303 7/20 0.32
SPHK1 Q9NYA1 3/20 0.33
HTT P42858 2/20 0.33
TSHR P16473 1/20 0.33
MAPT P10636 1/20 0.31
SMN1; SMN2 Q16637 1/20 0.31
EPHX1 P07099 2/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Buformin SCHEMBL11130179 0.89 GRIN2D (0.39) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
Buformin SCHEMBL15669256 0.87 GRIN2D (0.42) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
Buformin SCHEMBL6018 0.87 GRIN2D (0.42) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
Buformin SCHEMBL3644254 0.87 GRIN2D (0.42) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
Buformin SCHEMBL749659 0.87 GRIN2D (0.42) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
Buformin SCHEMBL3455307 0.85 GRIN2D (0.41) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
Buformin SCHEMBL4235633 0.85 GRIN2D (0.41) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
Buformin SCHEMBL22436277 0.85 GRIN2D (0.41) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
Buformin SCHEMBL5483046 0.85 GRIN2D (0.41) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
Buformin SCHEMBL1048416 0.85 GRIN2D (0.41) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Appears in 2373 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2853254-B1 A composition for lightening skin and/or hair SYMRISE AG (DE) 2017-11-08 EP claimed
EP-2320869-A1 SURFACTANT-FREE EMULSIONS WITH ANTI-AGING EFFECT, PRODUCTION THEREOF AND USE OF SAME HC Berlin Pharma Ag (DE) 2011-05-18 EP claimed
WO-2010012686-A1 SURFACTANT-FREE EMULSIONS WITH ANTI-AGING EFFECT, PRODUCTION THEREOF AND USE OF SAME HC BERLIN PHARMA AG (DE) 2010-02-04 WO claimed
EP-1455744-A2 COSMETIC AND/OR DERMATOLOGICAL ACTIVE INGREDIENT COMBINATION Beiersdorf AG (DE) 2004-09-15 EP claimed
WO-2003032941-A2 COSMETIC AND/OR DERMATOLOGICAL ACTIVE INGREDIENT COMBINATION BEIERSDORF AG (DE) 2003-04-24 WO claimed
EP-3801448-B1 WAX DISPERSIONS WITH CONDITIONING PROPERTIES BASF SE (DE) 2024-07-10 EP disclosed
EP-4282853-A1 PROCESS FOR THE PREPARATION OF MESACONIC ACID ESTERS Symrise AG (DE) 2023-11-29 EP disclosed
EP-2958546-B1 MEDICAMENT FOR TREATING THE SKIN AGEING CAUSED BY UV RADIATION SYMRISE AG (DE) 2023-11-22 EP disclosed
WO-2023186910-A1 PHOTOPROTECTIVE COMPOSITION FOR PROTECTING THE SKIN FROM VISIBLE LIGHT STADA ARZNEIMITTEL AG (DE) 2023-10-05 WO disclosed
EP-4252737-A1 SUNSCREEN COMPOSITION FOR PROTECTING THE SKIN FROM VISIBLE LIGHT STADA ARZNEIMITTEL AG (DE) 2023-10-04 EP disclosed
EP-4247791-A2 NEW COOLANTS, AND PREPARATIONS CONTAINING SAME Symrise AG (DE) 2023-09-27 EP disclosed
EP-3536383-B1 CLEANING AND CARE PREPARATIONS COMPRISING A POLYOXYALKYLENE CARBOXYLATE PERFECT IDEAS GMBH (CH) 2023-09-27 EP disclosed
EP-0701814-A2 Cosmetic or dermatologic composition containing hydrophobised inorganic pigment to maintain the amount of the skin urocanic acid Beiersdorf Aktiengesellschaft (DE) 1996-03-20 EP disclosed
WO-1996002223-A1 EMULSIFIER-FREE, FINELY DISPERSED COSMETIC OR DERMATOLOGICAL OIL-IN-WATER TYPE PREPARATIONS BEIERSDORF AG (DE) 1996-02-01 WO disclosed
EP-0691126-A1 Cosmetic or dermatological compositions containing alpha hydroxy carboxylic acids and/or keto carboxylic acids and inorganic pigments Beiersdorf Aktiengesellschaft (DE) 1996-01-10 EP disclosed
EP-0691127-A1 Shower oil Beiersdorf Aktiengesellschaft (DE) 1996-01-10 EP disclosed
WO-1995017155-A1 W/O/W EMULSIONS BEIERSDORF AG (DE) 1995-06-29 WO disclosed
WO-1995005852-A1 AGENT AGAINST SENSITIVE, HYPERREACTIVE AND HYPOACTIVE STATES OF THE SKIN, FORMS OF ACNE, ATOPIC DERMATITIDES, PSORIASIS, PRURIGO, PHOTODERMATOSES, ICHTHYOSIS AND VIRAL INFECTIONS BEIERSDORF AG (DE) 1995-03-02 WO disclosed
EP-0120404-B1 PROCESS FOR PREPARING BENZAL CHLORIDES BAYER AG (DE) 1986-02-19 EP disclosed
EP-0120404-A1 Process for preparing benzal chlorides BAYER AG (DE) 1984-10-03 EP disclosed